U.S. prescription drug market lacks certain competitive features: case of biosimilars

Forbes

3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of claims challenging AbbVie’s Humira’s (adalimumab) “patent thicket.” 

Controversially, the judge explicitly questioned whether there’s anything “wrong with [a product having] 132 patents." By Easterbrook’s reasoning, building a patent fort to fend off competition in perpetuity is fine so long as the patents are legitimate.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder